Signal GLP-1 penetration in Europe is estimated at about 2% of the population
Summary
McKinsey cites an estimate of roughly 2 percent GLP-1 penetration in Europe, attributing the gap to weaker drug availability, tighter reimbursement, and lower obesity rates in some countries.
Classification
Main topicBio & Health Tech
Region menusGlobal
Occurrencescope:transnational · geo_region:europe
Impactscope:global
Time horizon0-3 years (2026-07-26)
Last updated2026-07-29 04:49:52
Evidence 2
- State of the Consumer 2026: When tech acceleration and cost pressures collide McKinsey & Company page=10;section=Chapter 2: The health revolution - Wearables and scientific breakthroughs are influencing consumer goals / Footnote 7 2026-06 accessed 2026-07-26
- State of the Consumer 2026: When tech acceleration and cost pressures collide McKinsey & Company page=10;section=Chapter 2: The health revolution - Wearables and scientific breakthroughs are influencing consumer goals 2026-06 accessed 2026-07-26
Part of trends 1
Directly linked issues 0
No objects.
Relation types: supports
Public id: fm-d74f5fc78228